← Back to Analyst Consensus 
SLS Buy
SELLAS Life Sciences Group, Inc.
Current Price —
Implied Upside —
Analysts 6
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | maintain | Buy → Buy | — | 42% |
| Jul 16, 2025 | Maxim Group | maintain | Buy → Buy | $7 | 42% |
| Nov 22, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $3 | 50% |
| Sep 7, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $3 | 50% |
| Nov 15, 2022 | Alliance Global Partners | maintain | — → Buy | $8 | 41% |
| Jun 28, 2022 | Cantor Fitzgerald | maintain | — → Overweight | $6 | 50% |
| Jul 21, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $18 | 50% |
| Nov 15, 2019 | Maxim Group | upgrade | Hold → Buy | $12 | 42% |
| Apr 8, 2019 | Alliance Global Partners | initiate | — → Buy | $4.5 | 41% |
| Nov 1, 2018 | Oppenheimer | initiate | — → Outperform | $13 | 52% |
| Jul 20, 2018 | Maxim Group | maintain | Buy → Buy | $5 | 42% |
| Apr 2, 2018 | HC Wainwright & Co. | initiate | — → Buy | $11 | 44% |
| Mar 19, 2018 | Maxim Group | upgrade | Hold → Buy | $0 | 42% |
Price Target Trend
Apr 26, 2026 Latest: $32.5 Oct 24, 2026
EPS Estimates
0q $-0.05
Lo: $-0.05 Hi: $-0.05
1 analysts +1q $-0.05
Lo: $-0.05 Hi: $-0.05
1 analysts +1y $-0.10
Lo: $-0.20 Hi: $0.00
2 analysts ▲1
0y $-0.20
Lo: $-0.20 Hi: $-0.20
1 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days